DOCSLIB.ORG

Drug Tariff Part VIIIA December 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Tariff Part VIIIA December 2019 12/2019 Part VIIIA BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Part VIIIA - Basic Prices of Drugs Product List Part VIIIA products A Abacavir 600mg / Lamivudine 30 19000 C Lupin Healthcare 300mg tablets (UK) Ltd Abatacept 125mg/1ml solution for 4 120960 C Orencia ClickJect injection pre-filled disposable devices Abatacept 125mg/1ml solution for 4 120960 C Orencia injection pre-filled syringes Acacia spray dried powder 250 g 1632 C J M Loveridge Ltd Acamprosate 333mg gastro- 168 3770 K A resistant tablets Acarbose 100mg tablets 90 2529 A Acarbose 50mg tablets 90 1458 A Acebutolol 100mg capsules 84 1497 C Sectral Acebutolol 200mg capsules 56 1918 C Sectral Acebutolol 400mg tablets 28 1862 C Sectral Aceclofenac 100mg tablets 60 962 A Acenocoumarol 1mg tablets 100 462 C Sinthrome Acetazolamide 250mg modified- 30 1666 C Diamox SR release capsules Acetazolamide 250mg tablets 112 1029 M Acetic acid 2% ear spray S 5ml 410 C EarCalm Acetone liquid 50 ml 112 A Acetylcysteine 200mg oral powder 30 11250 A sachets sugar free Acetylcysteine 2g/10ml solution for 10 2126 C Martindale infusion ampoules Pharmaceuticals Ltd Acetylcysteine 5% eye drops S 10 ml 3346 C Ilube Acetylcysteine 600mg capsules 30 3998 A Acetylcysteine 600mg effervescent 30 550 C tablets sugar free Aciclovir 200mg dispersible tablets 25 147 A Aciclovir 200mg tablets 25 133 M Aciclovir 200mg/5ml oral 125 ml 3578 A suspension sugar free Aciclovir 3% eye ointment S 4.5 g 934 C Zovirax Aciclovir 400mg dispersible tablets 56 1199 A Aciclovir 400mg tablets 56 310 M Aciclovir 400mg/5ml oral 100 ml 3949 A suspension sugar free Aciclovir 5% cream S 2g 121K A S 10 g 603 K A Aciclovir 800mg dispersible tablets 35 1099 A Aciclovir 800mg tablets 35 430 M Acipimox 250mg capsules 90 4633 C Olbetam Acitretin 10mg capsules 60 2380 A Acitretin 25mg capsules 60 5524 A Aclidinium bromide 375micrograms/ S 60 dose 3250 C Eklira dose dry powder inhaler 173 Part VIIIA 12/2019 BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Aclidinium bromide 396micrograms/ S 60 dose 3250 C Duaklir Genuair dose / Formoterol 11.8micrograms/dose dry powder inhaler Acrivastine 8mg capsules 12 320 C Benadryl Allergy Relief Adalimumab 20mg/0.2ml solution 2 35214 C Humira for injection pre-filled syringes Adalimumab 40mg/0.4ml solution 2 70428 C Humira for injection pre-filled disposable devices Adalimumab 40mg/0.4ml solution 2 70428 C Humira for injection pre-filled syringes Adapalene 0.1% / Benzoyl peroxide S 45 g 1953 C Epiduo 2.5% gel Adapalene 0.1% cream S 45 g 1643 C Differin Adapalene 0.1% gel S 45 g 1643 C Differin Adefovir 10mg tablets S 30 25222 C Hepsera Adrenaline (base) 150micrograms/ S 12399CJext 0.15ml (1 in 1,000) solution for injection pre-filled disposable devices Adrenaline (base) 150micrograms/ S 12645CEpiPen Jr. 0.3ml (1 in 2,000) solution for injection pre-filled disposable devices 25290CEpiPen Jr. Adrenaline (base) 1mg/1ml (1 in 10 897 K A 1,000) solution for injection ampoules Adrenaline (base) 1mg/1ml (1 in S 11188A 1,000) solution for injection pre-filled syringes Adrenaline (base) 300micrograms/ S 12645CEpiPen 0.3ml (1 in 1,000) solution for injection pre-filled disposable devices Adrenaline (base) 500micrograms/ 10 8057 A 0.5ml (1 in 1,000) solution for injection ampoules Adrenaline (base) 500micrograms/ S 12699CEmerade 0.5ml (1 in 1,000) solution for injection pre-filled disposable devices Agomelatine 25mg tablets 28 3056 K A Alendronic acid 10mg tablets 28 189 M Alendronic acid 70mg / S 42280CFosavance Colecalciferol 70microgram tablets Alendronic acid 70mg effervescent S 42280CBinosto tablets sugar free Alendronic acid 70mg tablets S 495M Alendronic acid 70mg/100ml oral 42858A solution unit dose sugar free 174 12/2019 Part VIIIA BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Alfacalcidol 1microgram capsules S 30 1382 A Alfacalcidol 250nanogram capsules S 30 493 A Alfacalcidol 2micrograms/ml oral S 10 ml 2130 C One-Alpha drops sugar free Alfacalcidol 500nanogram capsules S 30 990 A Alfentanil 1mg/2ml solution for 10 634 C Rapifen injection ampoules Alfentanil 5mg/10ml solution for 51450CRapifen injection ampoules 10 2780 C Hameln Pharmaceuticals Ltd Alfentanil 5mg/1ml solution for 10 2319 C Rapifen Intensive injection ampoules Care Alfuzosin 10mg modified-release 30 1251 C tablets Alfuzosin 2.5mg tablets 60 158 M Alginate raft-forming oral 150 ml 258 C Gaviscon Original suspension sugar free Aniseed Relief 300 ml 433 C Gaviscon Original Aniseed Relief 500 ml 195 C Peptac liquid 600 ml 711 C Gaviscon Original Aniseed Relief Alimemazine 10mg tablets 28 11288 A Alimemazine 30mg/5ml oral 100 ml 24351 A solution Alimemazine 7.5mg/5ml oral 100 ml 17958 A solution Alirocumab 150mg/1ml solution for 2 33600 C Praluent injection pre-filled disposable devices Alirocumab 75mg/1ml solution for 2 33600 C Praluent injection pre-filled disposable devices Aliskiren 150mg tablets 28 2851 C Rasilez Aliskiren 300mg tablets 28 3427 C Rasilez Alitretinoin 10mg capsules 30 49372 C Toctino Alitretinoin 30mg capsules 30 49372 C Toctino Allopurinol 100mg tablets 28 134 M Allopurinol 300mg tablets 28 230 M Almond oil liquid 50 ml 95 C Thornton & Ross Ltd Almotriptan 12.5mg tablets 6 1612 K A Alogliptin 12.5mg / Metformin 1g 56 2660 C Vipdomet tablets Alogliptin 12.5mg tablets 28 2660 C Vipidia Alogliptin 25mg tablets 28 2660 C Vipidia Alogliptin 6.25mg tablets 28 2660 C Vipidia Alpha tocopheryl acetate 500mg/ 100 ml 6797 A 5ml oral suspension § Alprostadil 10microgram powder S 1924CCaverject and solvent for solution for injection vials 175 Part VIIIA 12/2019 BASIC PRICES OF DRUGS Drug Quantity Basic Price Category § Alprostadil 1mg urethral sticks S 11156CMuse § Alprostadil 20microgram powder S 11194CCaverject and solvent for solution for injection vials § Alprostadil 250microgram urethral S 11130CMuse sticks § Alprostadil 3mg/g cream 4 4000 C Vitaros § Alprostadil 40microgram powder S 12158CCaverject and solvent for solution for injection vials § Alprostadil 500microgram urethral S 11130CMuse sticks Alum powder 500 g 647 C J M Loveridge Ltd Aluminium chloride 20% solution S 20 ml 351 C Driclor S 60 ml 251 C Anhydrol Forte S 75 ml 348 C Driclor Aluminium chloride 20% spray S 30 ml 669 C Odaban Aluminium hydroxide 475mg 120 1371 C Alu-Cap capsules Alverine 120mg capsules 60 2329 A Alverine 60mg capsules 100 715 M Amantadine 100mg capsules 56 3601 M Amantadine 50mg/5ml oral solution 150 ml 12970 L A sugar free Ambrisentan 10mg tablets 30 161808 C Volibris Ambrisentan 5mg tablets 30 161808 C Volibris Amiloride 5mg / Bumetanide 1mg 28 5600 A tablets Amiloride 5mg tablets 28 1235 M Amiloride 5mg/5ml oral solution 150 ml 4235 A sugar free Aminophylline 250mg/10ml solution 10 850 C Hameln for injection ampoules Pharmaceuticals Ltd Aminophylline hydrate 225mg 56 240 C Phyllocontin modified-release tablets Continus Aminophylline hydrate 350mg 56 422 C Phyllocontin Forte modified-release tablets Continus Aminosalicylic acid gastro-resistant 30 33100 C Granupas granules 4g sachets sugar free Amiodarone 100mg tablets 28 163 A Amiodarone 200mg tablets 28 282 A Amiodarone 300mg/10ml solution S 11468A for injection pre-filled syringes Amisulpride 100mg tablets 60 986 M Amisulpride 100mg/ml oral solution S 60 ml 6497 K A sugar free Amisulpride 200mg tablets 60 1410 M Amisulpride 400mg tablets 60 4208 A Amisulpride 50mg tablets 60 637 M Amitriptyline 10mg tablets 28 101 M Amitriptyline 10mg/5ml oral solution 150 ml 13647 A sugar free 176 12/2019 Part VIIIA BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Amitriptyline 25mg tablets 28 87 M Amitriptyline 25mg/5ml oral solution 150 ml 1800 A sugar free Amitriptyline 50mg tablets 28 201 M Amitriptyline 50mg/5ml oral solution 150 ml 1920 A sugar free Amlodipine 10mg / Valsartan 160mg 28 2651 C Exforge tablets Amlodipine 10mg tablets 28 87 M Amlodipine 10mg/5ml oral solution 150 ml 11573 A sugar free Amlodipine 5mg / Valsartan 160mg 28 2651 C Exforge tablets Amlodipine 5mg / Valsartan 80mg 28 2011 C Exforge tablets Amlodipine 5mg tablets 28 85 M Amlodipine 5mg/5ml oral solution 150 ml 7578 A sugar free Amlodipine 5mg/5ml oral 150 ml 7000 C Essential suspension sugar free Pharmaceuticals Ltd Ammonium bicarbonate powder 500 g 458 C J M Loveridge Ltd Amorolfine 5% medicated nail S 5ml 792 M lacquer Amoxicillin 125mg/1.25ml oral R 20 ml 318 C Amoxil suspension paediatric Amoxicillin 125mg/5ml oral R 100 ml 173 M suspension Amoxicillin 125mg/5ml oral R 100 ml 135 M suspension sugar free Amoxicillin 1g powder for solution 10 1096 C Amoxil for injection vials Amoxicillin 250mg capsules 15 87 M 21 122 M Amoxicillin 250mg/5ml oral R 100 ml 188 M suspension Amoxicillin 250mg/5ml oral R 100 ml 152 M suspension sugar free Amoxicillin 3g oral powder sachets 2999A sugar free Amoxicillin 500mg capsules 15 105 M 21 147 M Amoxicillin 500mg powder for 10 548 C Amoxil solution for injection vials Amphotericin B 50mg powder for S 1388CFungizone solution for infusion vials Intravenous Ampicillin 125mg/5ml oral R 100 ml 2986 A suspension Ampicillin 250mg capsules 28 2050 A Ampicillin 250mg/5ml oral R 100 ml 3886 A suspension Ampicillin 500mg capsules 28 4030 A Ampicillin 500mg powder for 10 7830 A solution for injection vials 177 Part VIIIA 12/2019 BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Anagrelide 500microgram capsules 100 39775 A Anakinra 100mg/0.67ml solution for 7 18361 C Kineret injection pre-filled syringes Anastrozole 1mg tablets 28 194 M Antazoline 0.5% / Xylometazoline S 10 ml 335 C Otrivine-Antistin 0.05% eye drops Apixaban 2.5mg tablets
Load more

Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5
    ANTICHOLINERGICS: Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5 J Bareham BSP © www.RxFiles.ca Aug 2021 WHENEVER POSSIBLE, AVOID DRUGS WITH MODERATE TO HIGH ANTICHOLINERGIC ACTIVITY IN OLDER ADULTS (>65 YEARS OF AGE) Low Anticholinergic Activity; Moderate/High Anticholinergic Activity -B in combo Beers Antibiotics Antiparkinsonian Cardiovascular Agents Immunosuppressants ampicillin *ALL AVAILABLE AS amantadine SYMMETREL atenolol TENORMIN azaTHIOprine IMURAN cefOXitin GENERIC benztropine mesylate COGENTIN captopril CAPOTEN cyclosporine NEORAL clindamycin bromocriptine PARLODEL chlorthalidone GENERIC ONLY hydrocortisone CORTEF gentamicin (Oint & Sol’n NIHB covered) carbidopa/levodopa SINEMET digoxin LANOXIN, TOLOXIN methylprednisolone MEDROL piperacillin entacapone COMTAN dilTIAZem CARDIZEM, TIAZAC prednisone WINPRED dipyridamole PERSANTINE, ethopropazine PARSITAN vancomycin phenelzine NARDIL AGGRENOX disopyramide RYTHMODAN Muscle Relaxants pramipexole MIRAPEX Antidepressants baclofen LIORESAL ( on intrathecal only) procyclidine KEMADRIN furosemide LASIX amitriptyline ELAVIL cyclobenzaprine FLEXERIL selegiline ELDEPRYL hydrALAZINE APRESOLINE clomiPRAMINE ANAFRANIL isosorbide ISORDIL methocarbamol ROBAXIN OTC trihexyphenidyl ARTANE desipramine NORPRAMIN metoprolol LOPRESOR orphenadrine NORFLEX OTC doxepin >6mg SINEQUAN Antipsychotics NIFEdipine ADALAT tiZANidine ZANAFLEX A imipramine TOFRANIL quiNIDine GENERIC ONLY C ARIPiprazole ABILIFY & MAINTENA
    [Show full text]
  • Bluecross Blueshield of Western New York Formulary 1 Please Bring This Guide with You the Next Time You Visit Your Doctor
    BlueCross BlueShield of Western New York Formulary 1 Please bring this guide with you the next time you visit your doctor. If you have questions about your prescription drug benefit, visit the Pharmacy Services section of the BlueCross BlueShield web site at www.bcbswny.com. CRP2107_009678.1 MG009678A (Revise Date 07/01/2021) A Division of HealthNow New York Inc. An independent licensee of the BlueCross BlueShield Association. The Cross and Shield are registered trademarks of the BlueCross BlueShield Association. Inside front cover TABLE OF CONTENTS INTRODUCTION . iii UNDERSTANDING THE SYMBOLS USED THROUGHOUT THIS BOOK . iii USING THIS FORMULARY BOOK TO HELP CONTAIN COSTS . iv Save Money on Your Prescription Drugs . iv Finding Medications in the Guide . v SECTION 1 — THERAPEUTIC DRUG CATEGORIES . 1 SECTION II — INDEX . 8 ii The BlueCross BlueShield of Western New York Formulary 1 is a list of drugs to help guide physicians and pharmacists to select the medication that provides the appropriate treatment for the best price. INTRODUCTION BlueCross Blue Shield of Western New York has established an independent committee of practicing physicians and a pharmacist to help ensure that our formularies are medically sound and that they support your patients’ health. This committee—called the Pharmacy and Therapeutics Committee—reviews and evaluates medications on the formulary based on safety and efficacy to help maintain clinical integrity in all therapeutic categories. UNDERSTANDING THE SYMBOLS USED THROUGHOUT THIS BOOK Throughout this book, you will see certain symbols that indicate a management program is in place for selected medications. The symbols are as follows: Key P = A step edit applies to this drug.
    [Show full text]
  • Updates in Pediatric Dermatology
    Peds Derm Updates ELIZABETH ( LISA) SWANSON , M D ADVANCED DERMATOLOGY COLORADO ROCKY MOUNTAIN HOSPITAL FOR CHILDREN [email protected] Disclosures Speaker Sanofi Regeneron Amgen Almirall Pfizer Advisory Board Janssen Powerpoints are the peacocks of the business world; all show, no meat. — Dwight Schrute, The Office What’s New In Atopic Dermatitis? Impact of Atopic Dermatitis Eczema causes stress, sleeplessness, discomfort and worry for the entire family Treating one patient with eczema is an example of “trickle down” healthcare Patients with eczema have increased risk of: ADHD Anxiety and Depression Suicidal Ideation Parental depression Osteoporosis and osteopenia (due to steroids, decreased exercise, and chronic inflammation) Impact of Atopic Dermatitis Sleep disturbances are a really big deal Parents of kids with atopic dermatitis lose an average of 1-1.5 hours of sleep a night Even when they sleep, kids with atopic dermatitis don’t get good sleep Don’t enter REM as much or as long Growth hormone is secreted in REM (JAAD Feb 2018) Atopic Dermatitis and Food Allergies Growing evidence that food allergies might actually be caused by atopic dermatitis Impaired barrier allows food proteins to abnormally enter the body and stimulate allergy Avoiding foods can be harmful Proper nutrition is important Avoidance now linked to increased risk for allergy and anaphylaxis Refer severe eczema patients to Allergist before 4-6 mos of age to talk about food introduction Pathogenesis of Atopic Dermatitis Skin barrier
    [Show full text]
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information
    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • FDA Briefing Document Pulmonary-Allergy Drugs Advisory Committee Meeting
    FDA Briefing Document Pulmonary-Allergy Drugs Advisory Committee Meeting August 31, 2020 sNDA 209482: fluticasone furoate/umeclidinium/vilanterol fixed dose combination to reduce all-cause mortality in patients with chronic obstructive pulmonary disease NDA209482/S-0008 PADAC Clinical and Statistical Briefing Document Fluticasone furoate/umeclidinium/vilanterol fixed dose combination for all-cause mortality DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the supplemental New Drug Application (sNDA) 209482, for fluticasone furoate/umeclidinium/vilanterol, as an inhaled fixed dose combination, for the reduction in all-cause mortality in patients with COPD, to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]